Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier LabfiledCriticalServier Lab
Priority to UY29688ApriorityCriticalpatent/UY29688A1/en
Publication of UY29688A1publicationCriticalpatent/UY29688A1/en
La presente invención se refiere a una nueva forma cristalina V de agomelatina, a su procedimiento de preparación, así como a las composiciones farmacéuticas que la contienen como principio activo. La obtención de esta forma cristalina tiene por ventaja permitir la preparación de formulaciones farmacéuticas con una composición constante y reproducible, presentando características de disolución particularmente interesantes, lo cual resulta particularmente ventajoso cuando estas formulaciones están destinadas para la administración oral.The present invention relates to a new crystalline form V of agomelatine, to its preparation process, as well as to pharmaceutical compositions containing it as active ingredient. Obtaining this crystalline form has the advantage of allowing the preparation of pharmaceutical formulations with a constant and reproducible composition, presenting particularly interesting dissolution characteristics, which is particularly advantageous when these formulations are intended for oral administration.
UY29688A2006-07-202006-07-20
NEW CRYSTAL FORM V OF AGOMELATINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
UY29688A1
(en)
PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF GLUCOPIRANOSIL DIFENYLMETHANE, PHARMACEUTICAL FORM OF THE SAME, PROCEDURE FOR THEIR PREPARATION AND USES OF THE SAME FOR IMPROVED GLUCEMIC CONTROL IN A PATIENT.
Compounds derived from 2,7-diazaspirocycles, inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1; pharmaceutical composition comprising said compounds; Useful to treat obesity, diabetes, glucose intolerance, type II diabetes, among other diseases.
Compounds derived from benzo (1,4) dioxin-2-ylmethyl-sulfamide; pharmaceutical compositions containing them; process to prepare them and use in the treatment of anxiety, epilepsy, pain, substance abuse, related disorders, among others.